J 2022

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

CATTANEO, Chiara, Jon SALMANTON-GARCIA, Francesco MARCHESI, Shaimaa EL-ASHWAH, Federico ITRI et. al.

Basic information

Original name

Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

Authors

CATTANEO, Chiara, Jon SALMANTON-GARCIA (guarantor), Francesco MARCHESI, Shaimaa EL-ASHWAH, Federico ITRI, Barbora WEINBERGEROVÁ (203 Czech Republic, belonging to the institution), Da Silva Maria GOMES, Michelina DARGENIO, Julio DAVILA-VALLS, Sonia MARTIN-PEREZ, Francesca FARINA, Van Doesum JAAP, Toni VALKOVIC, Caroline BESSON, Christian Bjorn POULSEN, Alberto LOPEZ-GARCIA, Pavel ZAK, Martin SCHONLEIN, Klara PIUKOVICS, Ozren JAKSIC, Alba CABIRTA, Natasha ALI, Uluhan SILI, Nicola FRACCHIOLLA, Giulia DRAGONETTI, Tatjana ADZIC-VUKICEVIC, Monia MARCHETTI, Marina MACHADO, Andreas GLENTHOJ, Olimpia FINIZIO, Fatih DEMIRKAN, Ola BLENNOW, Maria Chiara TISI, Ali S OMRANI, Milan NAVRATIL, Zdenek RACIL, Jan NOVAK, Gabriele MAGLIANO, Moraima JIMENEZ, Carolina GARCIA-VIDAL, Nurettin ERBEN, Del Principe Maria ILARIA, Caterina BUQUICCHIO, Rui BERGANTIM, Josip BATINIC, Murtadha AL-KHABORI, Luisa VERGA, Tomas SZOTKOWSKI, Michail SAMARKOS, Irati ORMAZABAL-VELEZ, Stef MEERS, Johan MAERTENS, Laszlo Imre PINCZES, Martin HOENIGL, Lubos DRGONA, Annarosa CUCCARO, Yavuz M BILGIN, Avinash AUJAYEB, Laman RAHIMLI, Stefanie GRAFE, Mariarita SCIUME, Milos MLADENOVIC, Gokce Melis COLAK, Maria Vittoria SACCHI, Anna NORDLANDER, Caroline Berg VENEMYR, Michaela HANAKOVA, Nicole GARCIA-POUTON, Ziad EMARAH, Giovanni Paolo Maria ZAMBROTTA, Raquel Nunes RODRIGUES, Raul CORDOBA, Gustavo-Adolfo MENDEZ, Monika M BIERNAT, Oliver A CORNELY and Livio PAGANO

Edition

Cancers, Basel, MDPI, 2022, 2072-6694

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30205 Hematology

Country of publisher

Switzerland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 5.200

RIV identification code

RIV/00216224:14110/22:00128418

Organization unit

Faculty of Medicine

UT WoS

000887127200001

Keywords in English

haematological malignancy onset; COVID-19; treatment; outcome; prognostic factors

Tags

Tags

International impact, Reviewed
Změněno: 31/1/2023 08:54, Mgr. Tereza Miškechová

Abstract

V originále

Simple Summary Patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 are an even greater challenge for hematologists. To better clarify their outcome, we describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Overall, 343 (76.2%) patients received treatment for HM, and an overall response rate was observed in 140 (40.8%) patients after the first line of treatment. Thirty-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004). Statistical analysis showed that, together with age, severe/critical COVID-19, >= 2 comorbidities, lack of HM treatment was an independent risk factors for mortality. These observations suggest the importance of HM treatment in these patients; therefore, it should be delivered as soon as possible for patients requiring immediate therapy. Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, >= 2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.